PUBLISHER: DelveInsight | PRODUCT CODE: 1126009
PUBLISHER: DelveInsight | PRODUCT CODE: 1126009
DelveInsight's "Cholangiocarcinoma (CCA)- Epidemiology Forecast-2032" report delivers an in-depth understanding of the Cholangiocarcinoma, historical and forecasted epidemiology as well as the Cholangiocarcinoma trends in the United States, EU-5 (Germany, Spain, Italy, France, and United Kingdom), and Japan.
Study Period: 2019-2032.
The DelveInsight's Cholangiocarcinoma epidemiology report gives a thorough understanding of Cholangiocarcinoma. Cholangiocarcinoma is a type of cancer that forms in the slender tubes (bile ducts) that carry the digestive fluid bile. Bile ducts connect your liver to your gallbladder and to your small intestine. Cholangiocarcinoma (CCA) tumors can arise from anywhere in the biliary tract and may be difficult to identify based on histopathologic analysis alone. Cholangiocarcinoma can be anatomically differentiated into intrahepatic CCA (ICC) and extrahepatic CCA (ECC).
Unfortunately, the outlook is bleak. Most patients have an advanced or incurable illness when they are diagnosed, leaving systemic therapy as their sole choice for treatment. It is generally known that subgroups vary in their tumor biology and clinical presentation in addition to their varied etiological sources. Surgery may be curative for individuals with resectable illness when they first arrive, although these patients make up a small percentage with substantial recurrence rates. Additionally, the recurrence patterns often prohibit additional curative resection.
The best method for extending survival is still total surgical resection (R0); however, disease recurrence is not unheard of. Furthermore, patient comorbidities sometimes precluded surgical intervention, even if it could technically be done. Therefore, in order to increase survival in such a population, reduced morbidity interventional procedures must be developed. Early research on the genetic pathophysiology of CCAs concentrated on determining the carcinogenic function of certain genes, which were frequently discovered to be mutated in other cancers or altered by copy number changes. Studies have demonstrated that the genetic profiles of intrahepatic cholangiocarcinoma (CCA), extrahepatic cholangiocarcinoma, and gallbladder cancers are diverse; in fact, 50% of patients have actionable mutations such as FGFR, IDH1, HER2, and BRAF.
For a definitive diagnosis, patients usually undergo endoscopic retrograde cholangiopancreatography and procedures such as cytology, brushing, FISH (fluorescence in situ hybridization)-polisomy, biopsy, ultrasonography, choledochoscopy, cholangioscopy, chromoendoscopy, confocal endoscopy, narrow-band imaging. MRI, CT, endoscopic ultrasonography, or 18FDG PET-CT cannot definitively demonstrate the stricture's neoplastic nature.
Surgery with complete resection represents the only treatment for CCA with curative intent. Other treatment approaches may include liver transplantation which is associated with rapid tumor recurrence and low survival, and it has historically not been recommended as a treatment for unresectable CCA. Chemotherapy for patients presenting with unresectable or metastatic CCA, systemic chemotherapy remains the mainstay palliative treatment modality, and the role of adjuvant chemotherapy is not clearly defined in CCA, but for patients with local recurrence after resectioning pCCA, chemotherapy has been recommended.
The epidemiology section provides insights about the historical and current Cholangiocarcinoma patient pool and forecasted trends for individual seven major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the report also provides the diagnosed patient pool and their trends along with assumptions undertaken.
The disease epidemiology covered in the report provides a historical as well as forecasted Cholangiocarcinoma epidemiology scenario in the 7MM covering the United States, EU-5 countries (Germany, Spain, Italy, France, and the United Kingdom), and Japan from 2019 to 2032.
In the year 2021, the total diagnosed incident cases of CCA were 46,466 in the 7MM which are expected to grow during the study period, i.e., 2019-2032.
The disease epidemiology covered in the report provides historical as well as forecasted Cholangiocarcinoma epidemiology [segmented as Total Diagnosed-incidence Cases of Cholangiocarcinoma, Total Type-specific Cases of Cholangiocarcinoma, Total Age-specific Cases of Cholangiocarcinoma, Total Stage-specific Cases of Cholangiocarcinoma, Total Mutation-specific Cases of Cholangiocarcinoma, and Total Treated Cases (across lines) of Cholangiocarcinoma] in the 7MM covering the United States, EU-5 countries (Germany, France, Italy, Spain, and the United Kingdom), and Japan from 2019 to 2032.
The epidemiology segment also provides the Cholangiocarcinoma epidemiology data and findings across the United States, EU-5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.
According to the DelveInsight, in the year 2021, the total diagnosed incident cases of CCA were 10,034 in the United States which are expected to grow during the study period, i.e., 2019-2032.
The highest number of total incident cases of CCA was observed in Italy among the EU5 countries with 6,489 cases in 2021 which are expected to grow during the study period, i.e., 2019-2032.
In the year 2021, the total diagnosed incident cases of CCA were 16,004 in Japan which are expected to grow during the study period, i.e., 2019-2032.
To keep up with the current Cholangiocarcinoma patient pool and forecasted trend, we take KOLs and SMEs ' opinions working in the Cholangiocarcinoma domain through primary research to fill the data gaps and validate our secondary research. Their opinion helps to understand and validate the patient pool and forecasted trend.